IRCT20191217045763N1 IRCT 2020-11-29 Semnan University of Medical Sciences Ganoderma lucidum in Non alcoholic fatty liver disease patient Effects of Ganoderma lucidum on laboratory change in Non alcoholic fatty liver disease patient in 12 week clinical trial 2020-01-22 anticipated 80 Complete https://irct.ir/trial/44702 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 Condition 1: Non alcoholic fatty liver disease. Condition 2: Fatty liver disease. Intervention 1: Intervention group receive 3 capsules daily containing whole powder of Ganoderma lucidum, 220 mg; pure aqueous extract of Ganoderma lucidum, 30 mg standardized based on 17 micrograms per 1 mg total, produced by Ki Daroo Technology Company, the Ministry of Health license code 1681449932720180. It is mentioned to patients that follow exercise programs and a low-fat diet. The laboratory test including CBC diff, BUN, Cr, ALT, AST, FBS will be done at the beginning of the study by the end of the twelfth week. Intervention 2: Control group: recieve reutin tratment. It is mentioned to patients that follow exercise programs and a low-fat diet. The laboratory test including CBC diff, BUN, Cr, ALT, AST, FBS will be done at the beginning of the study by the end of the twelfth week. Yes - There is a plan to make this available What will be shared: Some information When: 6 month after article publition To whom: All Conditions: With reference Where to obtain: E-mail How to obtain: In 15 day with my E-mail Comments: